Click any tag below to further narrow down your results
Links
The article argues that AI will revolutionize drug discovery long before it can streamline clinical development, creating an abundance of candidate molecules but leaving patient trials as the main constraint. As discovery becomes commoditized and more assets target the same biology, real value will hinge on predictive toxicity, clinical efficacy, and strategic trial design.
This post lists nine key quotes from a San Francisco talk by Demis Hassabis and Sebastian Mallaby covering everything from OpenAI’s 50% bankruptcy risk to the need for new “AlphaFold” moments in drug discovery. They debate AGI probabilities, frontier cyber defense access, global AI optimism, and the economic and philosophical challenges of a post-scarcity future.
AWS introduced Amazon Bio Discovery, an AI-driven platform that lets researchers run complex drug-design workflows without coding. It provides a library of biological foundation models, an AI agent for workflow setup and analysis, and links to lab partners for synthesis and testing, cutting months of work down to weeks.